0.33
0.00%
Close of 9 Nov 2026, in AUD
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
About Island Pharmaceuticals
Its shares trade on ASX under the ticker ILA.AX. It has been listed since 13 April 2021. In the fiscal year to 30 June 2025, it reported revenue of A$58,800 and a net loss of A$3.9m. At that date it held total assets of A$7.5m and shareholders' equity of A$7.2m.
Island Pharmaceuticals Ltd. is a drug research and repurposing company, focused on developing preventative or therapeutic drugs for viral infections. The company is headquartered in Melbourne, Victoria. The company went IPO on 2021-04-13. The firm is engaged in drug research and repurposing. The company is focused on developing preventative or therapeutic drugs for viral infections. The firm's lead asset, ISLA-101 is developed by its subsidiary, Isla Pharmaceuticals. ISLA-101 is a drug with a safety profile, being repurposed for the prevention and treatment of dengue fever and other mosquito (or vector) borne diseases. The drug also has the potential to be used to prevent or treat a number of viruses including dengue, Zika and chikungunya, and other diseases rife in tropical climates. The firm is also considering alternative formulations, including a long-acting oral formulation and intravenous formulations for severe dengue infections. The firm's subsidiary is Isla Pharmaceuticals Inc.
Figures and description from our data supplier, not checked against the company's own report.
Company facts
- Sector
- Health Care
- Industry
- Pharmaceuticals
- Listed since
- 13 Apr 2021
- Website
- islandpharmaceuticals.com ↗
Leadership
Pay as last reported
- Mr. Jason CarrollNon-Executive Chairman of the Board
- Dr. David FosterChief Executive Officer, Managing Director, Executive Director, since 2020A$289,960
- Mr. Cameron JonesChief Financial Officer, Company Secretary, since 2024
- Mr. Christopher NtoumenopoulosNon-Executive Director
Environmental, social and governance
Scores out of 100, from our data supplier
- Overall
- 0
- Environment
- 0
- Social
- 0
- Governance
- 0
SWOT analysis
AI-generated by our data supplier. Not written or checked by our editors.
Strengths
- Headquartered in Melbourne, Victoria, Australia.
- Focused on developing preventative or therapeutic drugs for viral infections.
- Lead asset ISLA-101 is repurposed for dengue fever and other vector-borne diseases.
Weaknesses
- No specific weaknesses mentioned in the provided information.
- The company's lead asset ISLA-101 is still under development.
- The firm's subsidiary Isla Pharmaceuticals Inc. is involved in drug development.
Opportunities
- Potential to expand ISLA-101 to prevent or treat additional viruses like Zika and chikungunya.
- Development of alternative formulations including long-acting oral and intravenous options.
- Growing market for drugs targeting tropical diseases in endemic regions.
Threats
- No specific threats mentioned in the provided information.
- Repurposing drugs may face regulatory challenges.
- Competition in the pharmaceutical sector for viral infection treatments.
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.